← Leaderboards
Christina A. Pacak
University Of Florida
$3,903,422
Attributed
$4,803,422
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,003,422 · 2
FDA$1,800,000 · 1
By mechanism
R01$3,954,305 · 2
R61$849,117 · 1
Top collaborators
- George V Aslanidi3 shared
Most similar at University Of Florida
Same institution · by research overlap
- Susana T Valente$35,884,894
- Gregory Scott Schultz$7,172,274
- Sankar Swaminathan$16,219,587
- Barry J. Byrne$9,633,932
- Rachel M Bailey$2,383,526
Others in their field
Other Emerging Leaders on “Variant”
- Yunda Huang · Fred Hutchinson Cancer Center$63,914,632
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Theresa Engel · Leidos Biomedical Research, Inc.$44,839,860
- Scott Topper · Broad Institute, Inc.$40,042,399
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Evan Z Macosko · Broad Institute, Inc.$29,606,858
Research focus
VariantEvaluationGene TherapyProteinsNuclearInduced Pluripotent Stem CellDependovirusGenesMouse ModelProtein ExpressionAllelesPhenotypeInheritedComplementAffectCellsDesignAlzheimer&AposComplexBiogenesisCell LineBinding SitesConditioningCell Growth
Grant awards (10)
Gene Therapy for Xeroderma Pigmentosum - Cockayne Syndrome.$420,393
R61 · FY2025 · NS · contact PI
Gene Therapy for Xeroderma Pigmentosum - Cockayne Syndrome.$428,724
R61 · FY2024 · NS · contact PI
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2023 · FD
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2022 · FD
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome$416,007
R01 · FY2022 · HL · contact PI
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2021 · FD
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome$407,553
R01 · FY2021 · HL · contact PI
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome$428,186
R01 · FY2020 · HL · contact PI
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome$439,235
R01 · FY2019 · HL · contact PI
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome$463,324
R01 · FY2018 · HL · contact PI